IFS and Psychedelics: What Happens to Your Parts, and How to Integrate the Journey

Something unexpected kept happening in the MDMA trials for PTSD. Nobody told participants about parts, and the therapists were trained to stay out of the way. Yet people kept turning inward and talking to pieces of themselves: the young one who was terrified, the angry one they had locked away, the one that kept them numb. They spoke to those parts with a compassion they could not reach on an ordinary day.

To anyone who knows Internal Family Systems (IFS), that is a familiar scene. It is what an IFS session looks like when it goes well. This guide explains why the two keep meeting, what psychedelics do to your parts in IFS terms, and how IFS is used before, during and after a journey. It also covers what the critics say, and the safety facts any honest article on this has to include.

What psychedelics do to your parts, in IFS terms

IFS sees the mind as a family of parts. Managers run your day and keep painful material out of sight. Firefighters rush in to douse pain once it breaks through. Exiles are the young, hurt parts the protectors are guarding. Underneath them all is Self: the calm, curious, compassionate presence that IFS says is in everyone and cannot be damaged. (If these terms are new, our guide to discovering your parts walks through them.)

Richard Schwartz, who developed IFS, describes the effect of psychedelics in those terms, consistently, across talks from 2021 to 2026:

• The protectors go to sleep. Psychedelics put "your managers to sleep basically for 40 minutes or whatever," he told the cognitive scientist John Vervaeke in October 2026 (John Vervaeke's channel).
• They don't die. Schwartz rejects the popular phrase "ego death". The protectors "don't die, they just kind of go to sleep for a while," and they wake up afterwards (Wisdom 2.0, 2024). That one point shapes everything IFS does around a session.
• Self comes forward on its own. With managers offline, a lot of Self becomes available at once: the curiosity, calm and compassion IFS calls the 8 C's.
• Exiles get an opening. The protectors were guarding something. When they rest, the parts they kept away come forward to be felt and witnessed, often all at once.

Different medicines seem to open different doors. MDMA keeps people in their bodies with their hearts wide open; high-dose ketamine takes them out of the body into a boundless, oceanic state, and much of the parts work happens on the way back. The table below sets out how IFS practitioners describe each one.

The observation that convinced the founder of IFS

Schwartz was not looking for psychedelics. Some years ago, Michael Mithoefer, a psychiatrist who led MAPS's early MDMA trials and is himself trained in IFS, called him with a finding. He had been tracking how often participants on MDMA started working with their parts with no cue from the therapists. Schwartz has retold the answer in talk after talk: with higher doses, about 80% did.

That figure is not just Schwartz's memory. It is written into MAPS's own treatment manual for MDMA-assisted therapy. Describing a small internal pilot within its study of veterans, firefighters and police officers with PTSD, the manual reports that participants "spontaneously brought up their awareness of different parts of themselves in 81% of the MDMA-assisted sessions." It goes further, in a section titled "IFS and MDMA-Assisted Psychotherapy Compared":

MAPS MDMA treatment manual (version 7, 2015): "Elements of IFS therapy: recognition of and un-blending from parts, increased access to 'self energy,' acknowledgment of and respect for protectors, and witnessing and unburdening of past traumas often occur in MDMA-assisted psychotherapy with little or no direction from the therapists. One way to describe the effects of MDMA is that it facilitates access to a high level of self energy..."

For IFS, this is the central point. The model claims that Self is in everyone and already knows how to heal, and that the therapist's job is mostly to help protectors make room. Here were people with severe PTSD doing exactly that, unprompted, the moment their protectors relaxed. As Schwartz put it to Vervaeke, it showed he "had just stumbled onto something that people know how to do once these protectors relax."

The overlap has since moved from trials into everyday practice. A 2026 survey of 50 licensed ketamine-assisted psychotherapy providers in the US, by researchers at UC San Francisco and Stanford, found that IFS was the most-used therapy among them, at 74%, ahead of humanistic and existential therapy at 62% (Buchanan et al., Journal of Psychoactive Drugs, 2026). Schwartz himself co-wrote a clinical manual for it in 2026 with psychiatrist David Lovas, psychologist Martha Sweezy and therapist Sunny Strasburg: Psychedelic Medicine & Internal Family Systems (IFS) Therapy.

To be precise about what MAPS did and didn't do: its manual recommends IFS training as one option among several models of the multiple mind, alongside Voice Dialogue and Psychosynthesis. It does not require it. MAPS founder Rick Doblin has said Mithoefer suggested simply using the IFS manual, and MAPS decided to write its own, drawing on IFS only in response to what comes up for each person (Greater Good Radio, 2025). From an IFS perspective that is fine. What matters is that people did the IFS moves without a script.

Before a journey: get your protectors on board

If psychedelics put protectors to sleep, the obvious risk is what happens when they wake up. Schwartz is direct about it: "part of the danger with psychedelics is that you can bypass protectors and get to exiles without permission," and then there is a backlash (Field Trip Health, 2022). He learned the same lesson without drugs, decades earlier. When he pushed past protectors to get to the pain, clients came back the next week worse.

So the IFS preparation for a psychedelic session is the same move IFS makes before any deep work: meet the protectors first, and go only with their permission. In his retreats, Schwartz says, "we don't let people go without permission from all these protectors," and he finds it makes journeys "calmer and deeper." The IFS practitioners we studied describe the preparation in similar steps:

1. Ask which parts have fears about the journey. Losing control, what others will see, what might come up, never coming back. Each fear belongs to a part, and each part gets heard.
2. Meet the part that wants it, too. Psychologist Nancy Morgan asks it a simple question: if this part gets what it hopes for, what does it hope will be different? Clinicians warn about one keen part signing up on behalf of the whole system. The parts it overrode tend to resist later.
3. Negotiate the intention with all of them. An intention that only one part wrote is an intention the others will fight.
4. Treat a "no" as information. If a protector won't agree, postpone. As therapist Sunny Strasburg puts it, declining the medicine is "therapy, too." The working rule in parts work: never go faster than the slowest part is ready to go.
5. Try one session, then re-evaluate. Therapist Curt Kearney, author of Psychedelics and Internal Family Systems, suggests making consent a two-session conversation and committing to one session rather than a series (Numinus, 2025).

None of this needs a drug. Getting to know your protectors, what they fear and what they guard, is the core of IFS whether or not a journey is ever on the table.

During: why a "bad trip" is often an exile

The IFS reading of a frightening psychedelic experience is one of its most useful contributions. "What are ordinarily thought of as bad trips," Schwartz says, "are generally just these exiles that come in because they have an opening" (Third Wave, 2025). With the protectors asleep, a young part stuck in a terrible moment finally reaches awareness, and its terror floods in as if it were the whole person.

Seen that way, the panic is not a malfunction to be shut down. It is a part asking for attention. The facilitator's job is to stay steady and help the person separate a little from that part, so that someone, the Self, is there to be with it. A facilitator who panics, or treats it as an emergency to stop, tells the exile that it really is too much, and things escalate. Schwartz is emphatic that the decisive factor is the facilitator's own state: "I can't overstate the importance of... the facilitator keeping the room full of Self energy" (Living Medicine Institute, 2024).

In practice, IFS-informed sitters talk much less than you might expect. At high doses they mostly stay silent and present, and the overt parts work happens as the medicine wears off. Clinicians call that window the "golden hour": protectors are still soft, Self is still close, and work that might take several ordinary sessions can happen quickly.

After: how to integrate a psychedelic experience with IFS

John Vervaeke put the field's consensus plainly in his conversation with Schwartz: after talking with many psychedelic therapists, he concluded the biggest issue is not the trip, it is the integration. This is where IFS has the most to offer, because it gives integration a concrete shape. It is not mainly about what you learned. As Kearney's book puts it, "integration is relationship": a question of who in you changed, and keeping up a relationship with them.

1. Write down who showed up. Parts, images, ages, body sensations, the moments of fear and the moments of relief. Name them in your own words.
2. Check in with your protectors first. They were asleep and woke to find something happened without them. IFS therapist Ted Riskin suggests the simplest question, "are you okay?", and acknowledging that it was scary not to be able to do their job (Living Medicine Institute, 2026). If one of them was bypassed, apologise to it. It sounds strange; it works.
3. Go back to the part you met. If an exile surfaced, return to it in the days after and ask what it wants from you now. If you promised it something, keep the promise. The unburdened boy or girl from the session needs visiting, not just remembering.
4. Watch for backlash, and don't read it as failure. A louder critic, a shame spiral, numbness, or an urge to dismiss the whole experience in the days after usually means a protector is back on duty and alarmed. Turn toward it with the same curiosity you would give any part. (Our article on why parts sabotage progress explains the pattern.)
5. Keep the thread alive for weeks, not days. Morgan says the real integration begins after the first few weeks. Revisit the music, the notes, your dreams; take the walks; do one thing differently that the part asked for.
6. Know when to get help. If distress, panic, sleeplessness or a sense of unreality lasts beyond a couple of weeks or keeps getting worse, see a professional, ideally one who knows both psychedelics and parts work.

Our free IFS worksheets include a parts map and protector check-ins you can use for exactly this kind of follow-up.

MDMA, ketamine, psilocybin, ayahuasca: how IFS practitioners describe them

These are clinicians' descriptions in IFS language, not pharmacology, and individual experiences vary widely.

Medicine	How IFS practitioners describe it
MDMA	You stay in your body and the heart opens; huge compassion and connection. UCSF physician Bob Grant calls it "the compassion medicine." It is the drug behind the MAPS observation above.
Ketamine	At high doses you leave the body for a vast, nondual state Schwartz calls the "big Self"; the parts work happens on the return. At low doses you stay present and protectors relax enough to talk. It is short and legally prescribable, which is why Schwartz's IFS retreats use it.
Psilocybin	Grant calls it "the connection medicine," though "not always compassionate." Psychiatrist Reed Robinson finds it brings more built-in insight than ketamine, so the guide can step back further.
Ayahuasca	Comes in waves over several hours; parts work happens as each wave recedes. Practitioners from ceremonial traditions stress that the ceremony is the smaller part of the work and most of it happens afterwards.

What the critics say, and how IFS answers

A pro-IFS article still owes you the objections. Here are the serious ones, and the IFS response to each.

"Taking a psychedelic breaks IFS's own rule." IFS says never to force your way past a protector, and a drug that puts protectors to sleep does exactly that. This point comes from inside IFS: Ted Riskin raises it himself. The IFS answer is the preparation and integration described above. You ask the protectors before the journey, you check in with them after, and you take their "no" seriously. Schwartz says that since he started working this way, backlash has been "very mild compared to what we get without the medicine." That is his clinical experience, not a measured result.

"There's no trial proving IFS works with psychedelics." True. As of November 2026 there is no controlled trial comparing IFS-guided psychedelic therapy with other approaches; even the 2026 ketamine survey notes that providers blend three or four methods and calls for comparative trials. IFS's own evidence is growing but early. The evidence for IFS includes a 2026 randomised trial of an online group IFS program for PTSD in which both IFS and a well-matched active comparison improved PTSD significantly, with no difference between them (Joss et al., Psychological Trauma, 2026). What exists for psychedelics specifically is the observation in MAPS's own manual and the fact that most ketamine clinicians already choose IFS. The open question is how it compares, not whether it fits.

"IFS can open things up too fast." One creator who was destabilised by an unguided LSD trip put it well: "IFS can be a map, but it's not a floor" (2026). IFS agrees about the exiles. Schwartz says "it's pretty safe to work with protectors but if you're gonna go to exiles you need to have somebody who knows what they're doing with you." Someone already destabilised needs grounding, sleep and support before any deep parts work, and good IFS practice paces to the slowest part.

"In a suggestible state, the framework shapes what people believe." This is a fair concern. Schwartz talks openly about spiritual guides and what he calls unattached burdens, and some practitioners share those beliefs. They are his views, not requirements of the model; he says you can be an atheist and do the training, and his own rule is to assume anything that shows up is a part until it proves otherwise. The model should help you relate to an experience, not hand you a worldview.

"The drug does the healing." This one IFS rejects outright. "The medicine expedites healing; it doesn't necessarily do the healing," Schwartz says, and he criticises ketamine clinics that give the drug and leave people on their own. Grant notes that ketamine's benefit "may only last one to ten days" unless the drug is repeated or combined with psychotherapy.

Safety and legal status (as of November 2026)

These facts change, so check them against current sources before you act on anything.

• Legal status. Psilocybin, MDMA and LSD are not FDA-approved for any use and remain federally illegal outside research and state programs. Two phase 3 trials of MDMA-assisted therapy for PTSD were positive (2021, 2023), but the FDA rejected the application in August 2024; the company, now renamed Resilient, has reportedly refiled. Compass Pathways says its psilocybin application for treatment-resistant depression is nearly complete. Esketamine (Spravato) is FDA-approved for depression, ordinary ketamine is prescribed off-label, and Oregon and Colorado run state-licensed psilocybin services.
• Who trials exclude. People with a personal or close family history of psychosis or bipolar disorder, and people with significant heart conditions.
• Lithium. In an analysis of online reports, 47% of 62 accounts of lithium taken with a classic psychedelic involved seizures (Nayak et al., 2021).
• Ayahuasca and antidepressants. Ayahuasca contains MAO inhibitors. Combined with SSRIs, SNRIs, MDMA or tramadol, it is the main route to serotonin toxicity (Malcolm & Thomas, 2022). Never stop an antidepressant on your own to make room for a journey; stopping carries its own risks.
• Difficult aftermaths are real. In a study of 608 people who had extended difficulties after psychedelic use, about a third said the problems lasted more than a year. Taking the drug in a guided setting was linked to a narrower range of difficulties (Evans et al., 2023).

Read through an IFS lens, these facts point the same way as Schwartz's own warnings: a skilled, Self-led guide, careful preparation with your protectors, and real integration afterwards.

You don't need psychedelics to reach Self

Schwartz's first reaction to the MDMA finding is the most reassuring line in this whole story: "we do fine without that." IFS was built without any drug. The shift psychedelics produce chemically, protectors stepping back so Self can come forward, is the shift IFS teaches you to make by asking. When Tim Ferriss said a live IFS session with Schwartz "feels very psychedelic," Schwartz answered that it reaches "the same state that shamans take people into" (The Tim Ferriss Show, 2021).

What the psychedelic research really shows is that Self was there all along, waiting for the protectors to make room. The medicines can make that room quickly, for a few hours. IFS makes it slowly, legally, and in a way your protectors agree to, which may be why it lasts.

Frequently Asked Questions

Do people naturally do IFS on psychedelics?

Often, yes. The MAPS treatment manual for MDMA-assisted therapy reports that in an internal pilot, participants spontaneously brought up their awareness of different parts of themselves in 81% of MDMA-assisted sessions, and that unblending, access to Self energy and unburdening often happened with little or no direction from the therapists. Richard Schwartz, who developed IFS, reads this as evidence that people already know how to relate to their parts once their protectors relax.

Is IFS used in MDMA or ketamine therapy?

Yes, though not as an official protocol. The MAPS MDMA manual says therapists may benefit from training in IFS or a similar model of the multiple mind, and MAPS wrote its own non-directive manual rather than adopting IFS wholesale. In ketamine-assisted psychotherapy, a 2026 survey of 50 licensed US providers found IFS was the most-used therapy, at 74%.

What happens to protectors during a psychedelic experience?

In the IFS view, protective parts temporarily relax or go to sleep, which lets Self come forward and gives exiled parts an opening to be felt. Schwartz rejects the term ego death for this: the protectors do not die, they rest for a while and come back afterwards, which is why IFS asks for their permission beforehand and checks in with them after.

What is protector backlash after a trip?

Backlash is a protective part reacting after it was bypassed: a louder inner critic, anxiety, shame, numbness or an urge to undo what happened, often in the days after a session. IFS treats it as a protector doing its job rather than a sign the journey failed. The response is to turn toward that part, acknowledge it was scared, and ask what it needs, and the best prevention is getting protectors on board before the session.

What is psychedelic integration?

Psychedelic integration is the work after a psychedelic experience: revisiting it, making sense of it, and carrying what it brought up into daily life through deliberate practice and support, as defined in a 2022 concept analysis by Bathje, Majeski and Kudowor. In IFS terms it means continuing the relationships with the parts that showed up, rather than only remembering the insights.

Can IFS help with psychedelic integration?

That is where IFS fits most naturally. Integration in IFS terms means building an ongoing relationship with the parts that showed up: checking in with protectors, returning to the exiled part that was met, keeping promises made to it, and watching for backlash. No study has yet tested IFS integration against other approaches, so treat it as a practice framework rather than a proven treatment.

Do you need psychedelics to do IFS?

No. IFS was developed without psychedelics and works by asking protective parts to step back so Self can come forward, which is the same shift psychedelics produce chemically. Schwartz's first reaction to the MDMA findings was that IFS does fine without them. The medicines can speed the process up; they are not required for it.

Are psychedelics legal or FDA-approved yet?

As of November 2026, no. Psilocybin, MDMA and LSD are not FDA-approved for any use and remain federally illegal outside research and state programs. The FDA rejected MDMA-assisted therapy for PTSD in August 2024, and a psilocybin application for treatment-resistant depression is close to being filed. Esketamine (Spravato) is FDA-approved for depression, and ketamine is prescribed off-label. Oregon and Colorado run state-licensed psilocybin services.

Related reading: Psychedelics and Personality Change: What the Science Actually Shows · IFS and the Inner Child: Understanding Exiles · IFS and Addiction Recovery